Compare MAPS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAPS | ACET |
|---|---|---|
| Founded | 2008 | 1947 |
| Country | United States | United States |
| Employees | 449 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 69.6M |
| IPO Year | N/A | 2017 |
| Metric | MAPS | ACET |
|---|---|---|
| Price | $0.66 | $6.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.61 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 685.1K | 92.6K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.45 |
| 52 Week High | $1.36 | $9.05 |
| Indicator | MAPS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 47.44 |
| Support Level | $0.65 | $6.54 |
| Resistance Level | $0.88 | $8.34 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 36.79 | 45.24 |
WM Technology Inc operates an online cannabis marketplace for consumers, together with a comprehensive set of e-commerce and compliance software solutions for cannabis businesses, which are sold to both storefront locations and delivery operators (retailers) and brands in the legalized cannabis markets in states and territories of the United States. Its comprehensive business-to-consumer and business-to-business suite of products affords cannabis retailers and brands of all sizes integrated tools to compliantly run their businesses and to reach, convert, and retain consumers.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.